---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023882"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:12:32.404674+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics Q3 2022: Cash $106.4M; ongoing epetraborole trial; NIAID contract up to $17.8M

## Summary
- Cash, cash equivalents and investments totaled $106.4M as of Sep 30, 2022; expected to fund operations through mid-2024.
- R&D expenses increased vs. Q3 2021 due to license fee, clinical activity, and personnel costs.
- Enrollment ongoing in pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease; Phase 2 top-line data expected ~9 months after enrollment completion.
- Awarded up to $17.8M NIAID contract to develop epetraborole for acute systemic melioidosis.
- Phase 1 study in Japanese subjects supports 500mg once-daily dose regardless of ADH genotype.

## SEC filing metadata
- accession: 0000950170-22-023882
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017022023882/0000950170-22-023882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017022023882/antx-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023882
- JSON: https://secwatch.observer/filing/0000950170-22-023882.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023882.txt

## Key facts
- Earnings Releases
  AN2 Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: AN2 Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000095017022023882/0000950170-22-023882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.